FI970907A0 - Pyridatsinokinoliiniyhdisteitä - Google Patents
PyridatsinokinoliiniyhdisteitäInfo
- Publication number
- FI970907A0 FI970907A0 FI970907A FI970907A FI970907A0 FI 970907 A0 FI970907 A0 FI 970907A0 FI 970907 A FI970907 A FI 970907A FI 970907 A FI970907 A FI 970907A FI 970907 A0 FI970907 A0 FI 970907A0
- Authority
- FI
- Finland
- Prior art keywords
- phenyl
- deriv
- substd
- opt
- furyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9321854 | 1993-10-22 | ||
| GB939321854A GB9321854D0 (en) | 1993-10-22 | 1993-10-22 | Pyridazino quinoline compounds |
| GB9417171 | 1994-08-25 | ||
| GB9417171A GB9417171D0 (en) | 1994-08-25 | 1994-08-25 | Pyridazino quinoline compounds |
| GB9402295 | 1994-10-20 | ||
| PCT/GB1994/002295 WO1995011244A1 (en) | 1993-10-22 | 1994-10-20 | Pyridazino quinoline compounds |
| FI961696 | 1996-04-18 | ||
| FI961696A FI113865B (fi) | 1993-10-22 | 1996-04-18 | Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI970907A FI970907A (fi) | 1997-03-03 |
| FI970907A0 true FI970907A0 (fi) | 1997-03-03 |
| FI114916B FI114916B (fi) | 2005-01-31 |
Family
ID=26303731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI961696A FI113865B (fi) | 1993-10-22 | 1996-04-18 | Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa |
| FI970907A FI114916B (fi) | 1993-10-22 | 1997-03-03 | Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino- [4,5-b]kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI961696A FI113865B (fi) | 1993-10-22 | 1996-04-18 | Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US5744471A (fi) |
| EP (2) | EP0724583B1 (fi) |
| JP (1) | JP3583132B2 (fi) |
| KR (1) | KR100261209B1 (fi) |
| CN (1) | CN1053189C (fi) |
| AT (2) | ATE198072T1 (fi) |
| AU (2) | AU688393B2 (fi) |
| CA (1) | CA2171332A1 (fi) |
| CZ (1) | CZ292311B6 (fi) |
| DE (2) | DE69426422T2 (fi) |
| DK (2) | DK0724583T3 (fi) |
| ES (2) | ES2241513T3 (fi) |
| FI (2) | FI113865B (fi) |
| GB (1) | GB9420590D0 (fi) |
| GR (1) | GR3035080T3 (fi) |
| HK (1) | HK1013997A1 (fi) |
| HU (1) | HUT74161A (fi) |
| IL (1) | IL111266A (fi) |
| MY (2) | MY124316A (fi) |
| NO (1) | NO306995B1 (fi) |
| NZ (2) | NZ329303A (fi) |
| PL (1) | PL180679B1 (fi) |
| PT (2) | PT724583E (fi) |
| RU (1) | RU2168511C2 (fi) |
| SG (2) | SG59971A1 (fi) |
| SI (2) | SI1004582T1 (fi) |
| SK (1) | SK282491B6 (fi) |
| TW (1) | TW406082B (fi) |
| UA (1) | UA60291C2 (fi) |
| WO (1) | WO1995011244A1 (fi) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9420590D0 (en) * | 1993-10-22 | 1994-11-30 | Zeneca Ltd | Pyridazino quinoline compounds |
| US6214826B1 (en) | 1994-11-12 | 2001-04-10 | Zeneca Limited | Pyridazino quinoline compounds |
| GB9422894D0 (en) * | 1994-11-12 | 1995-01-04 | Zeneca Ltd | Pyridazino quinoline compounds |
| GB9507318D0 (en) * | 1995-04-07 | 1995-05-31 | Zeneca Ltd | Alpha substituted pyridazino quinoline compounds |
| AU2420001A (en) * | 1999-12-23 | 2001-07-09 | Astrazeneca Ab | Methods and compositions for the treatment of pain |
| CN1434714A (zh) * | 1999-12-23 | 2003-08-06 | 阿斯特拉曾尼卡有限公司 | 治疗疼痛的方法和组合物 |
| PT1244662E (pt) * | 1999-12-23 | 2005-07-29 | Astrazeneca Ab | Derivado de piridazinoquinolina e metodo para o tratamento da dor |
| JP2003518500A (ja) * | 1999-12-23 | 2003-06-10 | アストラゼネカ・アクチエボラーグ | 痛みの処置のための方法および組成物 |
| US6787547B2 (en) | 1999-12-23 | 2004-09-07 | Astrazeneca Ab | Compound and method for the treatment of pain |
| US6730675B2 (en) | 1999-12-23 | 2004-05-04 | Astrazeneca Ab | Compounds and methods for the treatment of pain |
| US20050124622A1 (en) * | 1999-12-23 | 2005-06-09 | Brown Dean G. | Compounds and methods for the treatment of pain |
| US6943165B2 (en) * | 1999-12-23 | 2005-09-13 | Astrazeneca Ab | Compound and method for the treatment of pain |
| US20030176435A1 (en) * | 2002-12-17 | 2003-09-18 | Brown Dean Gordon | Compounds and methods for the treatment of pain |
| EP1244663B1 (en) * | 1999-12-23 | 2004-08-25 | AstraZeneca AB | Compounds and methods for the treatment of pain |
| EP1244664A1 (en) * | 1999-12-23 | 2002-10-02 | AstraZeneca AB | Compounds and methods for the treatment of pain |
| SI1244662T1 (fi) * | 1999-12-23 | 2005-08-31 | Astrazeneca Ab | |
| US6403818B1 (en) | 2000-02-28 | 2002-06-11 | Eisai Co., Ltd. | Process for producing α-hydroxy-carbonyl compound |
| WO2002026738A1 (en) * | 2000-09-29 | 2002-04-04 | Astrazeneca Ab | 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN |
| JP2004509963A (ja) * | 2000-09-29 | 2004-04-02 | アストラゼネカ・アクチエボラーグ | １，２，５，１０−テトラヒドロピリダジノ［４，５−ｂ］キノリン−１，１０−ジオン及び疼痛治療のためのその使用 |
| US6946463B2 (en) | 2000-09-29 | 2005-09-20 | Astrazeneca Ab | 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain |
| US6933297B2 (en) | 2000-09-29 | 2005-08-23 | Astrazeneca Ab | 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US6969723B2 (en) * | 2001-05-31 | 2005-11-29 | Sanofi - Aventis | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| WO2005012309A1 (en) * | 2003-08-04 | 2005-02-10 | Valery Khazhmuratovich Zhilov | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
| NZ587551A (en) | 2004-06-24 | 2012-01-12 | Vertex Pharma | 5-Amino-phenol derivatives such as 5-amino-2,4-di-tert-butyl-phenol |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| US20090105272A1 (en) * | 2005-12-24 | 2009-04-23 | Grootenhuis Peter D J | Prodrugs of modulators of ABC transporters |
| PL3219705T3 (pl) * | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu |
| KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
| US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9109972D0 (en) * | 1991-05-09 | 1991-07-03 | Ici Plc | Therapeutic compounds |
| GB9208511D0 (en) * | 1991-05-09 | 1992-06-03 | Ici Plc | Compounds |
| GB9420590D0 (en) * | 1993-10-22 | 1994-11-30 | Zeneca Ltd | Pyridazino quinoline compounds |
| GB9422894D0 (en) * | 1994-11-12 | 1995-01-04 | Zeneca Ltd | Pyridazino quinoline compounds |
| GB9507318D0 (en) * | 1995-04-07 | 1995-05-31 | Zeneca Ltd | Alpha substituted pyridazino quinoline compounds |
-
1994
- 1994-10-12 GB GB9420590A patent/GB9420590D0/en active Pending
- 1994-10-12 IL IL11126694A patent/IL111266A/xx not_active IP Right Cessation
- 1994-10-20 UA UA96041567A patent/UA60291C2/uk unknown
- 1994-10-20 SI SI9430476T patent/SI1004582T1/xx unknown
- 1994-10-20 NZ NZ329303A patent/NZ329303A/xx not_active IP Right Cessation
- 1994-10-20 PL PL94314041A patent/PL180679B1/pl not_active IP Right Cessation
- 1994-10-20 HU HU9600889A patent/HUT74161A/hu unknown
- 1994-10-20 DE DE69426422T patent/DE69426422T2/de not_active Expired - Fee Related
- 1994-10-20 EP EP94930275A patent/EP0724583B1/en not_active Expired - Lifetime
- 1994-10-20 PT PT94930275T patent/PT724583E/pt unknown
- 1994-10-20 WO PCT/GB1994/002295 patent/WO1995011244A1/en active IP Right Grant
- 1994-10-20 MY MYPI94002796A patent/MY124316A/en unknown
- 1994-10-20 DE DE69434380T patent/DE69434380T2/de not_active Expired - Fee Related
- 1994-10-20 CN CN94194578A patent/CN1053189C/zh not_active Expired - Fee Related
- 1994-10-20 ES ES00101917T patent/ES2241513T3/es not_active Expired - Lifetime
- 1994-10-20 CA CA002171332A patent/CA2171332A1/en not_active Abandoned
- 1994-10-20 AT AT94930275T patent/ATE198072T1/de not_active IP Right Cessation
- 1994-10-20 AU AU79440/94A patent/AU688393B2/en not_active Ceased
- 1994-10-20 DK DK94930275T patent/DK0724583T3/da active
- 1994-10-20 ES ES94930275T patent/ES2154686T3/es not_active Expired - Lifetime
- 1994-10-20 PT PT00101917T patent/PT1004582E/pt unknown
- 1994-10-20 CZ CZ19961138A patent/CZ292311B6/cs not_active IP Right Cessation
- 1994-10-20 RU RU96109470/04A patent/RU2168511C2/ru not_active IP Right Cessation
- 1994-10-20 SG SG1996007261A patent/SG59971A1/en unknown
- 1994-10-20 NZ NZ275472A patent/NZ275472A/en not_active IP Right Cessation
- 1994-10-20 KR KR1019960702011A patent/KR100261209B1/ko not_active IP Right Cessation
- 1994-10-20 DK DK00101917T patent/DK1004582T3/da active
- 1994-10-20 EP EP00101917A patent/EP1004582B1/en not_active Expired - Lifetime
- 1994-10-20 SI SI9430314T patent/SI0724583T1/xx unknown
- 1994-10-20 MY MYPI98002508A patent/MY132875A/en unknown
- 1994-10-20 AT AT00101917T patent/ATE295846T1/de not_active IP Right Cessation
- 1994-10-20 US US08/637,641 patent/US5744471A/en not_active Expired - Fee Related
- 1994-10-20 SG SG9900943A patent/SG92630A1/en unknown
- 1994-10-20 JP JP51152195A patent/JP3583132B2/ja not_active Expired - Fee Related
- 1994-10-20 SK SK504-96A patent/SK282491B6/sk not_active IP Right Cessation
- 1994-11-18 TW TW083110721A patent/TW406082B/zh not_active IP Right Cessation
-
1996
- 1996-04-18 FI FI961696A patent/FI113865B/fi active
- 1996-04-19 NO NO961584A patent/NO306995B1/no not_active IP Right Cessation
-
1997
- 1997-03-03 FI FI970907A patent/FI114916B/fi active IP Right Grant
-
1998
- 1998-03-19 US US09/044,109 patent/US6232313B1/en not_active Expired - Fee Related
- 1998-05-27 AU AU68999/98A patent/AU721139B2/en not_active Ceased
- 1998-12-24 HK HK98115415A patent/HK1013997A1/xx not_active IP Right Cessation
-
1999
- 1999-12-06 US US09/455,096 patent/US6103721A/en not_active Expired - Fee Related
-
2000
- 2000-12-14 GR GR20000402690T patent/GR3035080T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI961696A0 (fi) | Pyridatsinokinoliiniyhdisteitä | |
| ATE237596T1 (de) | Chinazolinderivate und deren verwendung als vegf hemmer | |
| ATE101181T1 (de) | Anti-krebs-verbindungen. | |
| ATE148700T1 (de) | Tricyclische heterocyclen als pge2-antagonisten | |
| SE9904177D0 (sv) | Novel compounds | |
| DE69207182T2 (de) | Antitumor anthracenderivate | |
| ES2063177T3 (es) | Antagonistas de calcio. | |
| ES2090701T3 (es) | Agentes antihelminticos de bencimidazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 114916 Country of ref document: FI |